ClinicalTrials.gg
Not yet recruitingNCT07134075Updated Aug 21, 2025

Intracochlear Injection of Glucocorticoid

A Phase 2 interventional study of intracochlear triamcinolone acetonide injection and intracochlear injection of dexamethasone through the round window membrane in Sudden Sensorineural Hearing Loss (SSNHL), sponsored by Eye & ENT Hospital of Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Eye & ENT Hospital of Fudan University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.

Planned enrollment
3rd of 15
150 · median 90
Started
2025
with 2 others
Phase 2
3 of 18
3 open now
Primary completion
2027-08
later than 4 of 10 live
Registered
12th of 18
by date
Lead sponsor
6 of 18
Eye & ENT Hospital of Fudan University

Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 2, reaches primary completion later than 4 of the 10 other live ones, and was the 12th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hearing Loss, Sudden with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, randomized pilot study. To verify safety and efficacy of intracochlear injection of glucocorticoid through the round window membrane in patients with total sudden sensorineural hearing loss safety and efficacy in total sudden sensorineural hearing loss patients as an early salvage therapy.

Read the detailed description

The main questions it aims to answer are:

  1. Whether is it safe when total sudden sensorineural hearing loss patients receive intracochlear injection of glucocorticoid through the round window membrane.
  2. Whether is it effective in reversing hearing capability when total sudden sensorineural hearing loss patients receive intracochlear injection of glucocorticoid through the round window membrane.
  3. Whether is intracochlear glucocorticoid injection more effective than intratympanic glucocorticoid injection for treating total sudden sensorineural hearing loss.
  4. Which glucocorticoid intracochlear injection is more effective in patients with total sudden sensorineural hearing loss.
03

Conditions studied

  • Sudden Sensorineural Hearing Loss (SSNHL)

Browse trials for

Keywords

  • intracochlear injection
  • glucocorticoid
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age between 18 and 65 years Unilateral idiopathic sudden sensorineural hearing loss greater than 95dB at the average of 4 frequencies (500 Hz, 1000 Hz, 2000 Hz and 4000 Hz) in PTA (contralateral hearing is less than 30dB) at the onset of sudden hearing loss Participant who were treated with standard treatment for 14 days, but no recovery was confirmed as type IV (final hearing level with hearing gain of ≤15 dB) at the end of the 14-day treatment

Exclusion criteria

Exclusion Criteria:

Bilateral sudden sensorineural hearing loss Hearing loss with known causes (e.g., Meniere's disease, retrocochlear pathology, history of otologic surgery, perilymphatic fistula, barotrauma) History in the past 6 months of ototoxic treatment such as chemotherapy, use of loop diuretics, high dose aspirin, etc History of sudden sensorineural hearing loss within the past 2 years History of ischemic diseases (cerebral infarction, myocardial infarction, peripheral arterial obstructive disease) Neuropsychiatric disorders (epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis) Severe hepatic or renal insufficiency The CT diagnosis is "abnormality of the round window niche"

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Group A: intracochlear triamcinolone acetonide injection

    intracochlear injection of triamcinolone acetonide through the round window membrane

    Drug: intracochlear triamcinolone acetonide injection

  • Experimental
    Group B: intracochlear dexamethasone injection

    intracochlear injection of dexamethasone through the round window membrane

    Drug: intracochlear injection of dexamethasone through the round window membrane

  • Experimental
    Group C: intracochlear dexamethasone injection and intratympanic dexamethasone injection

    intracochlear injection of dexamethasone through the round window membrane and intratympanic dexamethasone injection through the tympanic membrane

    Drug: intracochlear dexamethasone injection and intratympanic dexamethasone injection

  • Active comparator
    Group D: intratympanic dexamethasone injection

    intratympanic dexamethasone injection tympanic membrane,once every other day, for a total of 4 injections.

    Drug: intratympanic dexamethasone injection

Interventions

  • Drugintracochlear triamcinolone acetonide injection

    intracochlear triamcinolone acetonide injection of through the round window membrane

    Also known as: intracochlear triamcinolone acetonide (40mg/ml, 30μl)injection

  • Drugintracochlear injection of dexamethasone through the round window membrane

    intracochlear injection of dexamethasone sodium phosphate through the round window membrane

    Also known as: intracochlear injection of dexamethasone sodium phosphate(7.5mg/ml, 30μl)through the round window membrane

  • Drugintracochlear dexamethasone injection and intratympanic dexamethasone injection

    intracochlear dexamethasone sodium phosphate injection of through the round window membrane, intratympanic dexamethasone sodium phosphate injection through the tympanic membrane

    Also known as: intracochlear injection of dexamethasone sodium phosphate through the round window membrane (7.5mg/ml, 30μl) and intratympanic dexamethasone sodium phosphate injection (10mg/ml)

  • Drugintratympanic dexamethasone injection

    intratympanic dexamethasone sodium phosphate injection (10mg/ml) through tympanic membrane,once every other day, for a total of 4 injections.

    Also known as: intratympanic dexamethasone sodium phosphate injection (10mg/ml)

06

What researchers measure

Primary outcomes

  1. Change from Baseline in pure tone audiometry (PTA)

    hearing capacity of thresholds (PTA)

    Time frame: Baseline, Week 2, Week 4, Week12, Week24

  2. Change from Baseline in auditory brainstem response (ABR)

    hearing capacity of thresholds (ABR)

    Time frame: Baseline, Week 2, Week 4, Week12, Week24

  3. Change from Baseline in auditory steady state response (ASSR)

    hearing capacity of thresholds (ASSR)

    Time frame: Baseline, Week 2, Week 4, Week12, Week24

  4. Change from Baseline in speech Discrimination Scores

    hearing capacity of thresholds (speech Discrimination Scores)

    Time frame: Baseline, Week 2, Week 4, Week12, Week24

Secondary outcomes

  1. change from baseline in tinnitus handicap inventory

    The THI questionnaire includes functional, emotional, and catastrophic subscales. It consists of 25 questions. The total score is calculated by adding up the scores for all questions and classifying the severity of tinnitus as no handicap (0-16), mild handicap (18-36), moderate handicap (38-56), and severe handicap (58-100).

    Time frame: Baseline, Week2, Week4, Week12, Week24

  2. change from baseline in dizziness handicap inventory

    The 25-item self-report Dizziness Handicap inventory (DHI) validated questionnaire that assesses functional, emotional and physical domains. Responses are graded 0 (no), 2 (sometimes) or 4 (yes) with higher scores indicating greater impact of dizziness maximum and maximum score of 100 points (15 minutes).

    Time frame: Baseline, Week2, Week4, Week12, Week24

  3. change from baseline in quality of life score

    Quality of life questionnaire will be measured to compare the change in individual's health-related quality of life using face to face Interview for the scores. Higher scores mean better functioning or fewer symptoms.

    Time frame: Baseline, Week2, Week4, Week12, Week24

07

Study locations

1 site
  • Fenyang Road 83
    Shanghai, Shanghai Municipality 200031, China
    • Wei Li, MD, PhD · Contact619liwei@163.com · 0086-18301969566
    • Huawei Li, MD, Ph.D · Principal investigator
    • Wuqing Wang, MD, Ph.D · Principal investigator
    • Haibo Shi, MD, Ph.D · Sub investigator
    • Xinsheng Huang, MD, Ph.D · Sub investigator
08

References and documents

Publications

  • Lv J, Wang H, Cheng X, Chen Y, Wang D, Zhang L, Cao Q, Tang H, Hu S, Gao K, Xun M, Wang J, Wang Z, Zhu B, Cui C, Gao Z, Guo L, Yu S, Jiang L, Yin Y, Zhang J, Chen B, Wang W, Chai R, Chen ZY, Li H, Shu Y. AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a single-arm trial. Lancet. 2024 May 25;403(10441):2317-2325. doi: 10.1016/S0140-6736(23)02874-X. Epub 2024 Jan 24. PubMed 38280389 ↗
  • Choi JW, Lee CK, Kim SB, Lee DY, Ko SC, Park KH, Choi SJ. Potential benefits of salvage intratympanic dexamethasone injection in profound idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2219-2227. doi: 10.1007/s00405-020-05967-z. Epub 2020 Apr 15. PubMed 32296977 ↗
  • Plontke SK, Biegner T, Kammerer B, Delabar U, Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol. 2008 Apr;29(3):401-6. doi: 10.1097/MAO.0b013e318161aaae. PubMed 18277312 ↗
  • Matsui H, Lopez IA, Ishiyama G, Ishiyama A. Immunohistochemical localization of glucocorticoid receptors in the human cochlea. Brain Res. 2023 May 1;1806:148301. doi: 10.1016/j.brainres.2023.148301. Epub 2023 Mar 1. PubMed 36868509 ↗
  • Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol. 2007 Dec;28(8):1124-30. doi: 10.1097/MAO.0b013e31815aee21. PubMed 18043438 ↗
  • Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes LS, Shi H, Slattery WH, Telian SA, Vrabec JT, Reda DJ. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA. 2011 May 25;305(20):2071-9. doi: 10.1001/jama.2011.679. PubMed 21610239 ↗
  • Li W, Hartsock JJ, Dai C, Salt AN. Permeation Enhancers for Intratympanically-applied Drugs Studied Using Fluorescent Dexamethasone as a Marker. Otol Neurotol. 2018 Jun;39(5):639-647. doi: 10.1097/MAO.0000000000001786. PubMed 29649043 ↗
  • Silverstein H, Choo D, Rosenberg SI, Kuhn J, Seidman M, Stein I. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J. 1996 Aug;75(8):468-71, 474, 476 passim. PubMed 8828271 ↗
  • Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. Arch Otolaryngol. 1980 Dec;106(12):772-6. doi: 10.1001/archotol.1980.00790360050013. PubMed 7002129 ↗
  • McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979 Sep-Oct;88(5 Pt 1):585-9. doi: 10.1177/000348947908800501. PubMed 496191 ↗
  • SCHUKNECHT HF. Ablation therapy in the management of Meniere's disease. Acta Otolaryngol Suppl. 1957;132:1-42. No abstract available. PubMed 13457879 ↗
  • Fishman JM, Cullen L. Investigating sudden hearing loss in adults. BMJ. 2018 Nov 12;363:k4347. doi: 10.1136/bmj.k4347. No abstract available. PubMed 30420423 ↗
  • Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, Hollingsworth DB, Kelley DM, Kmucha ST, Moonis G, Poling GL, Roberts JK, Stachler RJ, Zeitler DM, Corrigan MD, Nnacheta LC, Satterfield L, Monjur TM. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary. Otolaryngol Head Neck Surg. 2019 Aug;161(2):195-210. doi: 10.1177/0194599819859883. PubMed 31369349 ↗

Individual participant data

Plan to share: No — The ethics committee may require approval for data sharing to ensure alignment with principles like beneficence and justice.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Aug 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 21, 2025
StartEst.
Aug 25, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134075
Collaborators
Shanghai Zhongshan Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Aug 25, 2025 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Aug 21, 2025

Study contacts

Wei Li, MD, Ph.D
Contact
619liwei@163.com
0086-18301969566
Yilai Shu, MD, Ph.D
principal investigator · Eye & ENT Hospital, Fudan University, Shanghai, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion